SRRK - Scholar Rock Holding Corp Stock Price, Fair Value and News

12.49USD-1.83 (-12.78%)Market Closed

Market Summary

USD12.49-1.83

Market Closed

-12.78%

SRRK Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

SRRK Stock Price

View Fullscreen

SRRK RSI Chart

SRRK Valuation

Market Cap

996.1M

Price/Earnings (Trailing)

-5.44

Price/Sales (Trailing)

35.34

Price/Free Cashflow

-6.55

SRRK Price/Sales (Trailing)

SRRK Profitability

Return on Equity

-100.27%

Return on Assets

-68.56%

Free Cashflow Yield

-15.26%

SRRK Fundamentals

SRRK Revenue

Revenue (TTM)

33.2M

SRRK Earnings

Earnings (TTM)

-183.3M

Earnings Growth (Yr)

-44.37%

Earnings Growth (Qtr)

-23.26%

Breaking Down SRRK Revenue

Last 7 days

-6.4%

Last 30 days

-8.8%

Last 90 days

-21.3%

Trailing 12 Months

58.7%

How does SRRK drawdown profile look like?

SRRK Financial Health

Current Ratio

6.58

Debt/Equity

0.24

Debt/Cashflow

-3.41

SRRK Investor Care

Shares Dilution (1Y)

46.90%

Diluted EPS (TTM)

-2.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	47.3M	42.7M	37.2M	33.2M
2021	15.1M	15.8M	18.2M	18.8M
2020	22.4M	21.3M	19.5M	15.4M
2019	0	0	0	20.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Scholar Rock Holding Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	peng katie	acquired	-	-	26,825	-
Feb 16, 2024	myles edward h	sold	-74,685	15.7432	-4,744	coo & cfo
Feb 16, 2024	qatanani mo	sold	-39,546	15.7432	-2,512	chief scientific officer
Feb 16, 2024	parlavecchio caryn	sold	-59,052	15.7432	-3,751	chro
Feb 16, 2024	ho junlin	sold	-54,928	15.7432	-3,489	general counsel
Feb 16, 2024	backstrom jay t.	sold	-182,842	15.7432	-11,614	chief executive officer
Feb 12, 2024	myles edward h	acquired	-	-	53,570	coo & cfo
Feb 12, 2024	backstrom jay t.	acquired	-	-	214,285	chief executive officer
Feb 12, 2024	marantz jing l.	acquired	-	-	72,855	chief medical officer
Feb 12, 2024	ho junlin	acquired	-	-	57,855	general counsel

Which funds bought or sold SRRK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	unchanged	-	-11,709,400	199,968,000	5.10%
May 17, 2024	Ikarian Capital, LLC	new	-	5,180,610	5,180,610	0.57%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-21.83	-260,909	736,525	-%
May 16, 2024	JANE STREET GROUP, LLC	added	95.52	1,989,930	4,339,090	-%
May 15, 2024	BARCLAYS PLC	reduced	-41.12	-1,136,000	1,422,000	-%
May 15, 2024	Quarry LP	new	-	26,640	26,640	-%
May 15, 2024	FRED ALGER MANAGEMENT, LLC	reduced	-9.07	-429,129	2,614,290	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	540	3,538,940	4,240,150	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	added	6.76	9,166	1,076,590	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-1.36	-10,667,000	145,777,000	0.02%

Are Funds Buying or Selling SRRK?

Are funds buying SRRK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRRK

No. of Funds

Unveiling Scholar Rock Holding Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	12.3%	8,963,835	SC 13G/A
Feb 14, 2024	arch venture fund viii, l.p.	-	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	7,706,883	SC 13G/A
Feb 14, 2024	orbimed advisors llc	4.1%	2,960,000	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	polaris venture partners vi, l.p.	3.3%	2,406,309	SC 13G/A
Feb 09, 2024	artal international s.c.a.	17.4%	12,834,446	SC 13G/A
Jan 26, 2024	blackrock inc.	6.9%	4,962,597	SC 13G
Oct 18, 2023	samsara biocapital, l.p.	11.0%	7,853,413	SC 13D/A
Feb 14, 2023	bb biotech ag	4.1%	2,132,725	SC 13G/A

Recent SEC filings of Scholar Rock Holding Corp

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 13, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 18, 2024	PRE 14A	PRE 14A
Apr 11, 2024	4	Insider Trading
Mar 19, 2024	10-K	Annual Report

Peers (Alternatives to Scholar Rock Holding Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Scholar Rock Holding Corp News

Latest updates

Scholar Rock Holding Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	-	33,193	4,049	5,464	4,595	4,708	3,436	3,037	3,900	5,030	7,573	4,774	5,039	3,106
Operating Expenses	-7.8%	40,428	43,862	43,147	40,126	39,413	42,541	34,868	31,915	29,540	26,655	23,362	22,724	19,920	21,880	18,425	14,809
S&GA Expenses	3.3%	10,815	10,470	11,074	10,760	10,362	11,276	9,265	9,366	7,760	8,272	6,365	5,822	5,856	6,181	4,710	4,070
R&D Expenses	-11.3%	29,613	33,392	32,073	29,366	29,051	31,265	25,603	22,549	21,780	18,383	16,997	16,902	14,064	15,699	13,715	10,739
Interest Expenses	12.0%	1,340	1,196	1,024	812	588	502	501	491	244	-	-	-	-	1.00	-942	948
Net Income	9.3%	-39,255	-43,297	-44,000	-7,950	-35,914	-37,507	-30,707	-27,671	-26,571	-23,561	-19,281	-17,070	-11,573	-16,147	-12,525	-10,755
Net Income Margin	-15.1%	-4.05*	-3.52*	-2.94*	-2.37*	-7.00*	-6.73*	-6.88*	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.5%	-29,024	-26,510	-35,216	-43,008	-32,997	-37,388	-32,796	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-14.1%	267	311	251	285	315	358	390	424	266	304	298	332	361	388	163	156	176	196	189	197	171
Current Assets	-14.3%	247	288	228	260	287	328	358	389	229	265	258	290	318	344	119	145	164	185	179	188	162
Cash Equivalents	-7.3%	94.00	102	68.00	108	151	103	133	306	100	215	176	207	159	163	56.00	115	95.00	39.00	33.00	114	67.00
Net PPE	-12.2%	4.00	5.00	5.00	6.00	7.00	7.00	8.00	9.00	9.00	10.00	10.00	9.00	9.00	8.00	6.00	4.00	4.00	4.00	4.00	3.00	4.00
Liabilities	-1.5%	85.00	86.00	83.00	82.00	86.00	98.00	97.00	95.00	95.00	132	111	115	120	128	100	74.00	77.00	83.00	67.00	68.00	73.00
Current Liabilities	14.6%	38.00	33.00	27.00	24.00	26.00	36.00	34.00	40.00	33.00	64.00	65.00	67.00	70.00	43.00	33.00	33.00	27.00	33.00	33.00	32.00	34.00
Short Term Borrowings	312.4%	6.00	1.00	-	-	-	-	1.00	12.00	7.00	2.00	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-8.4%	45.00	49.00	50.00	50.00	50.00	50.00	50.00	39.00	44.00	48.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	49.00	50.00	50.00	50.00	50.00	50.00	39.00	44.00	48.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-
Shareholder's Equity	-18.8%	183	225	168	203	229	260	293	330	171	172	187	217	241	261	63.00	82.00	99.00	113	122	129	98.00
Retained Earnings	-8.4%	-733	-676	-630	-587	-550	-510	-471	-428	-384	-376	-340	-302	-272	-244	-217	-194	-174	-157	-146	-130	-117
Additional Paid-In Capital	1.6%	916	901	798	790	779	772	766	758	556	548	527	519	512	505	281	276	273	271	268	259	215
Shares Outstanding	5.0%	80.00	76.00	56.00	55.00	52.00	52.00	79.00	42.00	37.00	35.00	37.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	158	-	-	-	110	-	-	-	532	-	-	-	340	-	-	-	185	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-33.3%	-49,785	-37,349	-32,273	-32,550	-43,054	-28,907	-26,483	-34,739	-42,565	-32,455	-35,977	-31,813	-26,544	-19,685	-23,395	-19,827	2,636	-16,067	-15,112	-16,406	-15,530
Share Based Compensation	17.5%	8,164	6,951	7,203	6,818	6,170	6,165	7,917	6,791	6,828	6,096	6,154	6,226	4,673	2,530	4,036	2,395	2,214	1,852	2,688	1,814	1,618
Cashflow From Investing	232.9%	33,384	-25,128	-8,473	-15,241	89,983	77.00	-145,721	44,522	-70,576	29,458	3,283	79,017	22,557	-122,641	-35,874	38,926	56,091	21,209	-72,169	21,102	-32,378
Cashflow From Financing	-93.2%	6,525	96,529	280	4,689	1,076	-970	-451	195,772	481	39,701	1,906	607	2,737	246,457	368	595	399	818	6,124	42,098	-157

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SRRK Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 43,094	$ 29,735
General and administrative	15,325	10,774
Total operating expenses	58,419	40,509
Loss from operations	(58,419)	(40,509)
Other income (expense), net	1,566	1,130
Net loss	$ (56,853)	$ (39,379)
Net loss per share, basic (in dollars per share)	$ (0.59)	$ (0.49)
Net loss per share, diluted (in dollars per share)	$ (0.59)	$ (0.49)
Weighted average common shares outstanding, basic (in shares)	95,892,601	79,610,059
Weighted average common shares outstanding, diluted (in shares)	95,892,601	79,610,059
Comprehensive loss:
Net loss	$ (56,853)	$ (39,379)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(142)	555
Total other comprehensive income (loss)	(142)	555
Comprehensive loss	$ (56,995)	$ (38,824)

SRRK Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 91,979	$ 101,855
Marketable securities	146,453	178,083
Prepaid expenses and other current assets	8,501	8,256
Total current assets	246,933	288,194
Property and equipment, net	4,038	4,600
Operating lease right-of-use asset	9,805	11,417
Restricted cash	2,407	2,407
Other long-term assets	4,102	4,417
Total assets	267,285	311,035
Current liabilities:
Accounts payable	2,868	3,465
Accrued expenses	21,411	20,449
Operating lease liability	7,619	7,408
Short-term debt	5,501	1,334
Other current liabilities	107	85
Total current liabilities	37,506	32,741
Long-term portion of operating lease liability	2,412	4,392
Long-term debt	44,594	48,684
Total liabilities	84,512	85,817
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 150,000,000 shares authorized; 79,744,654 and 75,979,495 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	80	76
Additional paid-in capital	916,017	901,471
Accumulated other comprehensive income (loss)	(50)	92
Accumulated deficit	(733,274)	(676,421)
Total stockholders' equity	182,773	225,218
Total liabilities and stockholders' equity	$ 267,285	$ 311,035

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Jay T. Backstrom M.D., M.P.H.
WEBSITE	https://scholarrock.com
INDUSTRY	Biotechnology
EMPLOYEES	114

Scholar Rock Holding Corp Frequently Asked Questions

What is the ticker symbol for Scholar Rock Holding Corp? What does SRRK stand for in stocks?

SRRK is the stock ticker symbol of Scholar Rock Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scholar Rock Holding Corp (SRRK)?

As of Fri May 17 2024, market cap of Scholar Rock Holding Corp is 996.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRRK stock?

You can check SRRK's fair value in chart for subscribers.

What is the fair value of SRRK stock?

You can check SRRK's fair value in chart for subscribers. The fair value of Scholar Rock Holding Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Scholar Rock Holding Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRRK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Scholar Rock Holding Corp a good stock to buy?

The fair value guage provides a quick view whether SRRK is over valued or under valued. Whether Scholar Rock Holding Corp is cheap or expensive depends on the assumptions which impact Scholar Rock Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRRK.

What is Scholar Rock Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SRRK's PE ratio (Price to Earnings) is -5.44 and Price to Sales (PS) ratio is 35.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRRK PE ratio will change depending on the future growth rate expectations of investors.